Evidence

Health Economics

Health, Wellness and Productivity

You are here

Costly Complications of Diabetes

The vast majority of members with diabetes have an A1C above ADA targets,1 putting them at risk for other costly comorbidities including cardiovascular disease.2

As many as 60% of people with diabetes experience non-severe hypoglycemic events (NSHE), which can happen any time, day or night. Nocturnal NSHEs are particularly problematic, not only disrupting sleep but also causing potentially serious falls and related injuries and negatively impacting next-day functioning and well-being.3

Improved Outcomes with Dexcom

Use of the Dexcom Continuous Glucose Monitoring System has been proven to improve diabetes outcomes across key measures of glycemic control, including:4

  • A1C reduction
  • Increased time spent in target range
  • Reduction in nocturnal hypoglycemia

 

Average 1.0% A1C reduction after 24 weeks with Dexcom CGM users on multiple daily injections (MDI) insulin regimen*4

 

 

79% reduction of median time spent in nocturnal hypoglycemia with Dexcom CGM use*4

 

*Study participants had type 1 diabetes

1

Selvin E, Parrinello CM, Daya N, Bergenstal RM. Trends in Insulin Use and Diabetes Control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care. 2016;39(3):e33-e35. doi:10.2337/dc15-2229.

2

Nathan D, Cleary PA, Backlund JC, Genuth SM, et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005;353:2643-53.

3

Brod M, Wolden M, Christensen T, Bushnell DM. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes, Obesity & Metabolism. 2013;15(6):546-557. doi:10.1111/dom.12070.

4

Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.